Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347311 | 0.95 | SLC5A2 (0.49) | SLC5A2LGALS8LGALS9LGALS1LGALS3 | |
| SCHEMBL19188686 | 0.92 | SLC5A2 (0.52) | SLC5A2LGALS8 | |
| SCHEMBL14949103 | 0.92 | SLC5A2 (0.52) | SLC5A2LGALS8 | |
| SCHEMBL23547671 | 0.87 | TSHR (0.44) | SLC5A2LGALS8TSHR | |
| SCHEMBL26554081 | 0.84 | TSHR (0.43) | SLC5A2LGALS8TSHR | |
| SCHEMBL4139162 | 0.79 | SLC5A2 (0.71) | SLC5A2 | |
| SCHEMBL20529512 | 0.79 | SLC5A2 (0.71) | SLC5A2 | |
| SCHEMBL19189965 | 0.79 | SLC5A2 (0.43) | SLC5A2LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL12636127 | 0.78 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL13370879 | 0.78 | SLC5A2 (0.53) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-7368475-B2 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA BVBA (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368475-B2 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA BVBA (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368475-B2 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA BVBA (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220251-A1 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA EUROPE B.V.B.A. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | SLC5A2 2758/4885LGALS8 3537/4885LGALS9 4442/4885 |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | NSUN2, SNRPA, SNRPF | SLC5A2 2758/4885LGALS8 3537/4885LGALS9 4442/4885 |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | SLC5A2 2758/4885LGALS8 3537/4885LGALS9 4442/4885 |
| US-20040220251-A1 | Furanose-type bicyclic carbohydrates with biological activity | MANBA, FBP1, GALE | SLC5A2 689/4885LGALS8 72/4885LGALS9 179/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | SLC5A2 2758/4885LGALS8 3537/4885LGALS9 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.